- Innocan Pharma (CSE:INNO) has announced it has filed an international patent application for a topical treatment for diabetes symptoms
- The patent application makes claims for topical administration using cannabinoids to treat diabetes, which will help the blood flow to peripheral areas
- In addition to the patent, the company is expanding its intellectual cannabis-based products portfolio to treat a range of skin conditions with unmet medical needs
- Shares of Innocan Pharma are up 3.57 per cent to C$0.58 as of market close
Innocan Pharma (INNO) has announced it has filed an international patent application for a topical treatment for symptoms of diabetes.
The patent application, called Topical Composition for the Treatment of Diabetic Symptoms, is claiming for several compositions to administer cannabinoids to treat diabetic-related conditions.
In particular, the compositions claim the treatment will enhance blood flow to peripheral areas in those with diabetic symptoms.
Diabetes is a chronic, metabolic disease that elevates levels of blood sugar that can lead to damage of the heart, blood vessels, eyes, kidneys and nerves.
Iris Bincovich, CEO of Innocan Pharma, said in a press release this patent positions the company as a major player in the field. As it currently stands, Innocan Pharma has 12 patents with additional ones coming down the pipeline.
Case in point, the company is expanding its portfolio of cannabis-based products for additional skin therapy treatments, such as inflammatory conditions with unmet medical needs.
Through its wholly-owned subsidiary in Israel, Innocan Pharma Ltd., the company focuses primarily on the development of drug delivery platforms using cannabidiol.
Shares of Innocan Pharma are up 3.57 per cent to C$0.58 as of market close.